361 related articles for article (PubMed ID: 20336375)
1. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
2. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
[TBL] [Abstract][Full Text] [Related]
3. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
[TBL] [Abstract][Full Text] [Related]
4. AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher disease.
McEachern KA; Nietupski JB; Chuang WL; Armentano D; Johnson J; Hutto E; Grabowski GA; Cheng SH; Marshall J
J Gene Med; 2006 Jun; 8(6):719-29. PubMed ID: 16528760
[TBL] [Abstract][Full Text] [Related]
5. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.
Marshall J; McEachern KA; Kyros JA; Nietupski JB; Budzinski T; Ziegler RJ; Yew NS; Sullivan J; Scaria A; van Rooijen N; Barranger JA; Cheng SH
Mol Ther; 2002 Aug; 6(2):179-89. PubMed ID: 12161184
[TBL] [Abstract][Full Text] [Related]
7. Value of plasma chitotriosidase to assess non-neuronopathic Gaucher disease severity and progression in the era of enzyme replacement therapy.
van Dussen L; Hendriks EJ; Groener JE; Boot RG; Hollak CE; Aerts JM
J Inherit Metab Dis; 2014 Nov; 37(6):991-1001. PubMed ID: 24831585
[TBL] [Abstract][Full Text] [Related]
8. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
9. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
11. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
Pastores GM
Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
[TBL] [Abstract][Full Text] [Related]
12. The metabolism of glucocerebrosides - From 1965 to the present.
Futerman AH; Platt FM
Mol Genet Metab; 2017; 120(1-2):22-26. PubMed ID: 27955980
[TBL] [Abstract][Full Text] [Related]
13. A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.
Westbroek W; Nguyen M; Siebert M; Lindstrom T; Burnett RA; Aflaki E; Jung O; Tamargo R; Rodriguez-Gil JL; Acosta W; Hendrix A; Behre B; Tayebi N; Fujiwara H; Sidhu R; Renvoise B; Ginns EI; Dutra A; Pak E; Cramer C; Ory DS; Pavan WJ; Sidransky E
Dis Model Mech; 2016 Jul; 9(7):769-78. PubMed ID: 27482815
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease: pathological mechanisms and modern management.
Jmoudiak M; Futerman AH
Br J Haematol; 2005 Apr; 129(2):178-88. PubMed ID: 15813845
[TBL] [Abstract][Full Text] [Related]
15. Impaired autophagic and mitochondrial functions are partially restored by ERT in Gaucher and Fabry diseases.
Ivanova MM; Changsila E; Iaonou C; Goker-Alpan O
PLoS One; 2019; 14(1):e0210617. PubMed ID: 30633777
[TBL] [Abstract][Full Text] [Related]
16. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
[TBL] [Abstract][Full Text] [Related]
17. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
[TBL] [Abstract][Full Text] [Related]
18. Gaucher Disease: A Glance from a Medicinal Chemistry Perspective.
Prencipe F; Barzan C; Savian C; Spalluto G; Carosati E; De Amici M; Mosconi G; Gianferrara T; Federico S; Da Ros T
ChemMedChem; 2024 May; 19(10):e202300641. PubMed ID: 38329692
[TBL] [Abstract][Full Text] [Related]
19. Substrate reduction therapy using Genz-667161 reduces levels of pathogenic components in a mouse model of neuronopathic forms of Gaucher disease.
Blumenreich S; Yaacobi C; Vardi A; Barav OB; Vitner EB; Park H; Wang B; Cheng SH; Sardi SP; Futerman AH
J Neurochem; 2021 Mar; 156(5):692-701. PubMed ID: 32743826
[TBL] [Abstract][Full Text] [Related]
20. A high throughput glucocerebrosidase assay using the natural substrate glucosylceramide.
Motabar O; Goldin E; Leister W; Liu K; Southall N; Huang W; Marugan JJ; Sidransky E; Zheng W
Anal Bioanal Chem; 2012 Jan; 402(2):731-9. PubMed ID: 22033823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
